Raghav Sai Pharmaceuticals.Ltd. Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.50 M
- Company Age 34 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 3.44%
- Profit Growth -3.39%
- Ebitda -22.02%
- Net Worth 10.49%
- Total Assets 6.38%
About Raghav Sai Pharmaceuticals.Ltd.
Raghav Sai Pharmaceuticals Pvt.Ltd. (RSPP) is a Private Limited Indian Non-Government Company incorporated in India on 23 August 1990 and has a history of 34 years and six months. Its registered office is in Hyderabad-434., Telangana.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anantham Jakkani, Venu Chepuri, and Balchander Arram serve as directors at the Company.
Company Details
- Location Hyderabad-434., Telangana
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239TG1990PTC011628
- Company No.
011628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Raghav Sai Pharmaceuticals.Ltd.?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anantham Jakkani  | Director | 26-Feb-2001 | Current |
| Venu Chepuri | Director | 26-Feb-2001 | Current |
| Balchander Arram | Director | 23-Aug-1990 | Current |
Financial Performance of Raghav Sai Pharmaceuticals.Ltd..
Raghav Sai Pharmaceuticals Pvt.Ltd., for the financial year ended 2023, experienced modest growth in revenue, with a 3.44% increase. The company also saw a slight decrease in profitability, with a 3.39% decrease in profit. The company's net worth Soared by an impressive increase of 10.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raghav Sai Pharmaceuticals.Ltd.?
In 2023, Raghav Sai Pharmaceuticals.Ltd. had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arcadia Pharma Specialities Private LimitedAnantham Jakkani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raghav Sai Pharmaceuticals.Ltd.?
Unlock and access historical data on people associated with Raghav Sai Pharmaceuticals.Ltd., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raghav Sai Pharmaceuticals.Ltd., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raghav Sai Pharmaceuticals.Ltd.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
